Daniel Galles is listed as a director and promoter on 12 SEC Form D filings by 5 issuers between Sep 2010 and Dec 2024: Clearsense, Inc (Brentwood, TN — industry reported as "Other" — 2019–2023; $49.9M reported sold to 11 investors), Gauss Surgical, Inc. (Los Altos, CA — other health care — 2016; $12.6M reported sold to 19 investors), PATHWAY MEDICAL TECHNOLOGIES INC (Kirkland, WA — biotechnology — 2010; $9.93M reported sold to 13 investors), RxRevu, Inc. (Denver, CO — other health care — 2021–2023; $8M reported sold to 44 investors) and ALLUMIA VENTURES FUND III, LP (Bellevue, WA — pooled investment fund — 2024).
What this means A repeat sponsor — 5 separate companies raised money with this person listed as director and promoter, over about 14 years. Across those companies the filings report $80.4M sold in total.
Listed alongside Albert Prast (7 shared filings), Eugene Scheurer (7 shared filings), Kirk Moquin (5 shared filings), Charles Boorady (4 shared filings), Dan Wildermuth (4 shared filings) and 33 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Daniel. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 12 public filings for Daniel Galles and found 13 differences, 1 worth asking the sponsor about: Form D filed 70 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.